Fig 1.
Recruitment, treatment and follow-up of PKDL patients.
Table 1.
Case definition for recording treatment outcome of PKDL patients.
Table 2.
Profile of patients treated with miltefosine and relapsed cases.*
Fig 2.
A PKDL patient (Case 11, table no. 3) that relapsed after MIL treatment and was subsequently cured with AmB.
Papulo-nodules present on face before treatment (A), and complete regression after 3 months of MIL treatment (B), relapse at 13 months after completion of MIL treatment with papules on the root of nose (C), and cured after treatment with AmB (D).
Fig 3.
Scatter plot showing parasite load at the pre-treatment stage in the cases that eventually relapsed vs those that remained cured.
Parasite load was determined by Q-PCR in slit aspirate sample at the time of diagnosis of PKDL and expressed as the number of Leishmania parasite/μl slit aspirate. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean± SEM.
Fig 4.
In vitro MIL susceptibility of parasite isolates from cured (n = 7) and relapsed (n = 6) PKDL patients.
MIL susceptibility at (A) promastigote stage (B) amastigote stage. Each individual value represents mean IC50± SD of the results from two separate assays. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean ±SEM.